IP Library Granted Patent US 10,105,405
Granted Patent B2
US 10,105,405 · App. 15/337,221 · Granted Oct 23, 2018

Compositions and methods for enhancing brain function using acetyl-L-carnitine, huperzine A and ginkgo biloba

Inventor: Josh Reynolds (Laguna Beach, CA)
Assignee: KeyView Labs, Inc.
A61K36/16A23L33/105A23L33/15A23L33/175A23L33/21A61K9/0053A61K9/28A61K31/164A61K31/197A61K31/205A61K31/22A61K31/221A61K31/223A61K31/381A61K31/4188A61K31/4375A61K31/4415A61K31/455A61K31/473A61K31/475A61K31/4748A61K31/7028A61K31/7034A61K36/185A61K36/41A61K36/77A61K36/82A61K45/06A23V2002/00
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 10,105,405
App. No.
15/337,221
Granted
Oct 23, 2018
Kind
B2
Abstract

A nutritional supplement composition is formulated for oral administration and enhances cognitive function. It includes huperzine A, Ginkgo biloba, and acetyl-L-carnitine. The huperzine A, acetyl-L-carnitine, and Ginkgo biloba together account for at least 80 wt % of a dosage unit of the composition. The Ginkgo biloba is about 5.0% to about 12.0%, by weight of the huperzine A, acetyl-L-carnitine and Ginkgo biloba. The Ginkgo biloba and acetyl-L-carnitine are in a ratio of y:z respectively, wherein y is between about 690 and 1,030 for Ginkgo biloba and z is between about 8,000 and 12,000 for acetyl-L-carnitine.

Claims (41)

1. A nutritional supplement composition for enhancing cognitive function, comprising:

huperzine A;

Ginkgo biloba; and

acetyl-L-carnitine;

wherein the composition is formulated for oral administration such that huperzine A, acetyl-L-carnitine, and Ginkgo biloba together account for at least 80 wt % of a dosage unit of the composition and the Ginkgo biloba is about 5.0% to about 12.0% by weight of the huperzine A, acetyl-L-carnitine and Ginkgo biloba, and the Ginkgo biloba and acetyl-L-carnitine are in a ratio of y:z respectively, wherein y is between about 690 and 1,030 for Ginkgo biloba and z is between about 8,000 and 12,000 for acetyl-L-carnitine.

2. The nutritional supplement composition of claim 1 , wherein the huperzine A, Ginkgo biloba, and acetyl-L-carnitine are in a ratio of x:y:z, respectively, wherein x is between about 0.85 and about 1.3 for huperzine A, y is between about 690 and about 1,030 for Ginkgo biloba, and z is between about 8,000 and about 12,000 for acetyl-L-carnitine.

3. The nutritional supplement composition of claim 2 , wherein x is between about 0.95 and about 1.20 for huperzine A, y is between about 775 and about 945 for Ginkgo biloba, and z is between about 9,000 and about 11,000 for acetyl-L-carnitine.

4. The nutritional supplement composition of claim 1 , wherein acetyl-L-carnitine is present in an amount from about 1,160 mg to about 1,860 mg.

5. The nutritional supplement composition of claim 1 , wherein Ginkgo biloba is present in an amount from about 100 mg to about 160 mg.

6. The nutritional supplement composition of claim 1 , wherein huperzine A is present in an amount from about 50 mcg to about 200 mcg.

7. The nutritional supplement composition of claim 1 , wherein the composition is formulated with an enteric coating.

8. The nutritional supplement composition of claim 1 , further comprising an inactive ingredient selected from the group consisting of a carrier, a binder, an excipient, a dye, and combinations thereof.

9. The nutritional supplement composition of claim 1 , wherein huperzine A, Ginkgo biloba, and acetyl-L-carnitine together account for at least 90 wt % of a dosage unit of the composition.

10. The nutritional supplement composition of claim 1 , wherein huperzine A, Ginkgo biloba, and acetyl-L-carnitine together account for at least 95 wt % of the dosage unit of the composition.

11. The nutritional supplement composition of claim 1 , wherein the dosage unit of the composition is equal to or less than about 1,500 mg.

12. A nutritional supplement composition for enhancing cognitive function, comprising:

huperzine A;

rhodiola;

Ginkgo biloba;

acetyl-L-carnitine;

biotin; and

alpha lipoic acid;

wherein the composition is formulated for oral administration such that the huperzine A, rhodiola, Ginkgo biloba, acetyl-L-carnitine, biotin, and alpha lipoic acid together account for at least 80 wt % of a dosage unit of the composition and the Ginkgo biloba is about 3.5 percent to about 8.5 percent by weight of the huperzine A, rhodiola, Ginkgo biloba, acetyl-L-carnitine, biotin and alpha lipoic acid and the alpha lipoic acid is about 11.0 percent to about 26.0 percent by weight of the huperzine A, rhodiola, Ginkgo biloba, acetyl-L-carnitine biotin and alpha lipoic acid, and the Ginkgo biloba and acetyl-L-carnitine are in a ratio of y:z respectively, wherein y is between about 690 and 1,030 for Ginkgo biloba, and z is between about 8,000 and 12,000 for acetyl-L-carnitine.

13. The nutritional supplement composition of claim 12 , wherein acetyl-L-carnitine is present in an amount from about 1,160 mg to about 1,860 mg.

14. The nutritional supplement composition of claim 12 , wherein rhodiola is present in an amount from about 250 mg to about 350 mg.

15. The nutritional supplement composition of claim 12 , wherein huperzine A is present in an amount from about 50 mcg to about 200 mcg.

16. The nutritional supplement composition of claim 12 , wherein Ginkgo biloba is present in an amount from about 100 mg to about 160 mg.

17. The nutritional supplement composition of claim 12 , further wherein alpha lipoic acid is present in an amount from about 300 mg to about 500 mg.

18. The nutritional supplement composition of claim 12 , wherein biotin is present in an amount from about 400 mcg to about 600 mcg.

19. The nutritional supplement composition of claim 12 , wherein the dosage unit of the composition is equal or less than about 1,500 mg.

20. A nutritional supplement composition for enhancing cognitive function, comprising:

huperzine A;

Ginkgo biloba; and

acetyl-L-carnitine;

wherein the composition is formulated for oral administration such that huperzine A, acetyl-L-carnitine, and Ginkgo biloba together account for at least 80 wt % of a dosage unit of the composition and the Ginkgo biloba is about 5.0% to about 12.0% by weight of the huperzine A, acetyl-L-carnitine and Ginkgo biloba, and wherein the Ginkgo biloba is present in an amount from about 100 mg to about 160 mg, and wherein the Ginkgo biloba and acetyl-L-carnitine are in a ratio of y:z respectively, wherein y is between about 690 and 1,030 for Ginkgo biloba and z is between about 8,000 and 12,000 for acetyl-L-carnitine.

21. The nutritional supplement composition of claim 20 , wherein the huperzine A, Ginkgo biloba, and acetyl-L-carnitine are in a ratio of x:y:z, respectively, wherein x is between about 0.85 and about 1.3 for huperzine A, y is between about 690 and about 1,030 for Ginkgo biloba, and z is between about 8,000 and about 12,000 for acetyl-L-carnitine.

22. The nutritional supplement composition of claim 20 , wherein x is between about 0.95 and about 1.20 for huperzine A, y is between about 775 and about 945 for Ginkgo biloba, and z is between about 9,000 and about 11,000 for acetyl-L-carnitine.

23. The nutritional supplement composition of claim 20 , wherein the composition is formulated with an enteric coating.

24. The nutritional supplement composition of claim 20 , further comprising an inactive ingredient selected from the group consisting of a carrier, a binder, an excipient, a dye, and combinations thereof.

25. The nutritional supplement composition of claim 20 , wherein huperzine A, Ginkgo biloba, and acetyl-L-carnitine together account for at least 95 wt % of the dosage unit of the composition.

26. The nutritional supplement composition of claim 20 , wherein the dosage unit of the composition is equal to or less than about 1,600 mg.

Assignments (2)
SECURITY INTEREST Recorded Mar 15, 2021
From: KEYVIEW LABS, INC.
To: PACIFIC WESTERN BANK (AS SUCCESSOR IN INTEREST BY MERGER TO SQUARE 1 BANK)
Reel/Frame 055593/0541 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jan 23, 2017
From: REYNOLDS, JOSH
To: KEYVIEW LABS, INC.
Reel/Frame 041043/0693 →
Continuity (7)
Continuation In Part 15078102 · Mar 23, 2016
Continuation 14453861 · Aug 7, 2014
Continuation In Part 13307587 · Nov 30, 2011
Continuation In Part 11758151 · Jun 5, 2007
Provisional Application 60803943 · Jun 5, 2006
Provisional Application 60820201 · Jul 24, 2006
Related Publication 20170042953A1 · Feb 16, 2017